Cannabis Science (CBIS) Issues Upbeat Report on its Subsidiary, Michigan Green Technologies (MGT), as Historic Michigan Milestone is Reached with New Hemp Legislation

COLORADO SPRINGS, Colo., Jan. 29, 2015 /PRNewswire/ -- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to issue an update regarding its subsidiary, Michigan Green Technologies LLC (MGT), and the positive evolution of the Michigan legal landscape.

Cannabis Science shares the mission of Michigan Green Technologies in bringing cannabis-based wellness solutions to the people of Michigan. MGT is recognized as the leading resource for Michigan legislative initiatives and management consulting in respect of cannabinoid-based drug development, nutraceuticals, food supplements, cosmeceuticals and food products.

"Michigan leaped forward with the passage into law of the state's hemp bills.  Cannabis Science is pleased with the strong, professional work of its Michigan-based operations and that of its many Michigan partners.  MGT represents an incredible assemblage of highly qualified individuals -- and the team continues to expand.  We look forward to more legislative progress in Michigan over the next few quarters, as Michigan's and MGT's business models mature in a parallel fashion," stated Robert Kane, Director & CFO, Cannabis Science Inc.

MGT celebrated this month's milestone victory:  the passage of Michigan's hemp bills. House Bills 5439 and 5440 were put into immediate effect and became Public Act 547.  As the state's legislative environment continues to mature, the prospects grow for MGT's successful development and delivery of quality cannabis-based care to patients in need.  Michigan's progressive, common sense approach to legislation is likely to make it a leading US state in which cannabis-based care is fully integrated into the general healthcare system, thus providing patients with effective products in a safe and regulated manner.

Other updates include the following:

• MGT continues development in preparation for projects with various of Michigan's universities to engage and invest in clinical research and educational programs;
• MGT progresses in securing a potent and talented advisory board that encompasses professionals and experts in law, medicine, law enforcement, state and federal government, and R & D;
• MGT has created a network of county governmental leaders throughout the state for the purpose of implementation of a statewide pilot program spanning all aspects of a robust hemp program, including education of key stakeholders;
• MGT is excited about the future of upcoming initiatives, such as the Michigan Medical Marihuana Act and related pending legislation, to rationalize and organize the state's cannabis program for safe, viable and effective patient care.

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.